Philip Marsden is a panelist during the session titled “Excessive prices in pharmaceutical markets.”
For more information on this event, click here.
How compulsory licensing shaped innovation in the Xerox case
In a new article published in the Journal of Industrial Economics, CRA’s Robin Mamrak shows that opening up an incumbent’s patent portfolio can promote...
